Fennec Pharmaceuticals is trading 5.1% up at $10.40, rebounding from yesterday’s decline as the stock benefits from a broader risk-on tone and strength across the biotech sector.
- The move tracks gains in the XBI biotech ETF and major U.S. indices, despite a lack of fresh company-specific news or regulatory filings today.
- Investors appear to be digesting previously reported strong Q1 2026 growth and sustained commercial momentum for PEDMARK rather than reacting to a new headline.